The BCR-ABL(35INS) insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Chronic myeloid leukemia is effectively treated with imatinib, but reactivation of BCR-ABL frequently occurs through acquisition of kinase domain mutations. The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP245...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: O'Hare, Thomas, Zabriskie, Matthew S., Eide, Christopher A., Agarwal, Anupriya, Adrian, Lauren T., You, Huihong, Corbin, Amie S., Yang, Fei, Press, Richard D., Rivera, Victor M., Toplin, Julie, Wong, Stephane, Deininger, Michael W., Druker, Brian J.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2011
Teme:
Myeloid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3217407/
https://ncbi.nlm.nih.gov/pubmed/21908430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-05-349191
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki